Detection of degradation products of canine NT-proBNP

• US 8,778,699 B2
• Filed: 08/04/2011
• Issued: 07/15/2014
• Est. Priority Date: 08/04/2010
• Status: Active Grant

• Current Assignee: IDEXX Laboratories Incorporated
• Original Assignee: IDEXX Laboratories Incorporated
• Inventors: Yerramilli, Mahalakshmi, Atkinson, Michael, Yerramilli, Murthy V. S. N.
• Primary Examiner(s): Gabel, Gail R
• Assistant Examiner(s): GRUN, JAMES LESLIE
• Application Number:
  US13/198,092
• Publication Number:
  US 20120034710A1
• Time in Patent Office: 1,076 Days
• Field of Search: 435/7.1, 435/7.92, 435/7.93, 435/7.94, 435/69.3, 435/70.21, 435/287.2, 435/287.9, 435/975, 436/501, 436/514, 436/518, 436/528, 436/531, 436/548, 436/8, 436/15, 436/87, 436/811, 436/817, 530/388.24, 530/389.2, 530/391.1, 530/391.3, 530/387.9, 422/425, 422/430
• US Class Current: 436/518
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: G01N 2333/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/7019 Ischaemia
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/545 Synthetic resin
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.

Claims

1. A method for determining an amount of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in a sample from a canine, comprising determining an amount of a polypeptide consisting of GRSPASEASEASEASGLWAVQ (SEQ ID NO:

22) in the sample, and correlating the amount of the polypeptide in the sample to the amount of NT-proBNP in the sample.

2. The method of claim 1, wherein the step of determining the amount of the polypeptide comprises contacting the sample with a first antibody that specifically binds a first epitope on SEQ ID NO:

22.

3. The method of claim 2, wherein the first antibody is a monoclonal antibody.

4. The method of claim 2, wherein the step of determining the amount of the polypeptide further comprises contacting the sample with a second antibody that specifically binds a second epitope on SEQ ID NO:

22, wherein the first epitope is different than the second epitope.

5. The method of claim 4, wherein the second antibody is a monoclonal antibody.

6. The method of claim 4, wherein the first antibody is bound to a solid phase and the second antibody is bound to a label.

7. The method of claim 4, wherein the first antibody is bound to a label and the second antibody is bound to a solid phase.

8. The method according to claim 1, wherein the step of determining the amount of NT-proBNP comprises mass spectroscopy.

9. A method for determining a presence or an amount of canine N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in a biological sample comprising detecting a degradation product of NT-proBNP in the sample, wherein the degradation product consists of SEQ ID NO:

22.

10. The method of claim 9, wherein the step of detecting the degradation product comprises contacting the sample with a first antibody that specifically binds a first epitope on SEQ ID NO:

22.

11. The method of claim 10, wherein the first antibody is a monoclonal antibody.

12. The method of claim 10, wherein the step of detecting the degradation product comprises contacting the sample with a second antibody that specifically binds a second epitope on SEQ ID NO:

22, wherein the first epitope is different than the second epitope.

13. The method of claim 12, wherein the second antibody is a monoclonal antibody.

14. The method of claim 12, wherein the first antibody is bound to a solid phase and the second antibody is bound to a label.

15. The method of claim 12, wherein the first antibody is bound to a label and the second antibody is bound to a solid phase.